Asthma Clinical Trial
Official title:
Effects of IL-4R-alpha Inhibition (Dupixent) Inhibition On The Respiratory Microbiome And Immunologic Correlates In Patients With Severe Asthma
Verified date | August 2023 |
Source | University of Michigan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall goal of this study is to understand biological responses related to dupilumab treatment among severe asthma patients. Not all asthma is the same, and characteristics of asthma vary from person to person. The study will investigate whether the study drug can help to improve the health of participants lungs, boost immune response, as well as improve quality of life.
Status | Completed |
Enrollment | 15 |
Est. completion date | June 29, 2023 |
Est. primary completion date | June 29, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Physician-diagnosed/managed severe asthma patients that are clinically eligible for dupilumab - Current treatment with a medium-to-high-dose inhaled glucocorticoid (fluticasone propionate at a total daily dose of greater or equal (=) 440 µg or equipotent equivalent) plus up to at least one additional controller (e.g., a long-acting ß2-agonist or leukotriene receptor antagonist) - Eosinophilic asthma phenotype (blood eosinophil level >300) or asthma requiring daily oral corticosteroids - Asthma that is uncontrolled, as defined by a score on the Asthma Control Test of 19 or lower, or a worsening of asthma in the past year that led to an asthma hospitalization, Emergency Department visit, or 3 days of oral corticosteroids - Severity of asthma that, in the opinion of the subject's asthma care specialist, requires dupilumab for control - For women of childbearing age: agree to use birth control or remain abstinent during the duration of the study. Exclusion Criteria: - Patients with diagnosis of other chronic lung diseases (e.g. Chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, Churg-Strauss syndrome, Allergic bronchopulmonary aspergillosis, etc.) - Current smoker or reported smoking within 1 month of the screening visit (tobacco or any inhaled recreational product) - Greater than 10 total pack-year of cigarette smoking history - Treatment with oral corticosteroids for an asthma exacerbation 1 month prior to screening or during the screening period - Use of any biologic therapy for asthma within the past 3 months - Respiratory or Gastrointestinal illness within 1 month prior to screening or during the screening period - Treatment with antibiotics for acute infections within six weeks prior to screening or during the screening period. - Pregnancy at enrollment or during the study - Known hypersensitivity to dupilumab or its excipients |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
Lead Sponsor | Collaborator |
---|---|
University of Michigan | Regeneron Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in alpha-diversity of respiratory microbiota | This will be profiled from induced sputum. | Baseline (before dupilumab), 1 month | |
Primary | Changes in alpha-diversity of respiratory microbiota | This will be profiled from induced sputum. | Baseline (before dupilumab), 4 month | |
Primary | Changes in alpha-diversity of respiratory microbiota | This will be profiled from induced sputum. | 1 month, 4 months | |
Primary | Change in beta-diversity of respiratory microbiota | This will be profiled from induced sputum. | Baseline (before dupilumab), 1 month | |
Primary | Change in beta-diversity of respiratory microbiota | This will be profiled from induced sputum. | Baseline (before dupilumab), 4 month | |
Primary | Change in beta-diversity of respiratory microbiota | This will be profiled from induced sputum. | 1 month, 4 months | |
Primary | Change in relative abundances of microbiota members | This will be profiled from induced sputum. | Baseline (before dupilumab), 1 month | |
Primary | Change in relative abundances of microbiota members | This will be profiled from induced sputum. | Baseline (before dupilumab), 4 month | |
Primary | Change in relative abundances of microbiota members | This will be profiled from induced sputum. | 1 month, 4 months | |
Primary | Change in respiratory bacterial burden | This will be profiled from induced sputum. | Baseline (before dupilumab), 1 month | |
Primary | Change in respiratory bacterial burden | This will be profiled from induced sputum. | Baseline (before dupilumab), 4 month | |
Primary | Change in respiratory bacterial burden | This will be profiled from induced sputum. | 1 month, 4 months | |
Primary | Changes in alpha-diversity of stool microbiota | This will be based on stool samples. | Baseline (before dupilumab), 1 month | |
Primary | Changes in alpha-diversity of stool microbiota | This will be based on stool samples. | Baseline (before dupilumab), 4 month | |
Primary | Changes in alpha-diversity of stool microbiota | This will be based on stool samples. | 1 month, 4 months | |
Primary | Change in beta-diversity of stool microbiota | This will be based on stool samples. | Baseline (before dupilumab), 1 month | |
Primary | Change in beta-diversity of stool microbiota | This will be based on stool samples. | Baseline (before dupilumab), 4 month | |
Primary | Change in beta-diversity of stool microbiota | This will be based on stool samples. | 1 month, 4 months | |
Secondary | Forced expiratory volume ( FEV1) / forced vital capacity (FVC) ratio | This will be based on Spirometry | up to 4 months | |
Secondary | Forced expiratory volume (FEV1) | This will be based on Spirometry | up to 4 months | |
Secondary | Change in Fractional exhaled nitric oxide (FeNO) | Baseline, 4 months | ||
Secondary | Asthma Control Test (ACT) | This is a self-administered 5 item questionnaire. The ACT score is the sum of the values for all 5 items. The scores range from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. An ACT score >19 indicates well-controlled asthma; the minimal clinically important difference in score is 3. | up to 4 months | |
Secondary | Mini Asthma Quality of Life Questionnaire Score (mAQLQ) | This is a patient self-administered questionnaire with 15 questions covering 4 domains: Symptoms (5 questions), Activity Limitations (4 questions), Emotional Function (3 questions), and Environmental Stimuli (3 questions). Scores range from 0-6 (lower is worse). The mini AQLQ score is calculated as the average of domain items. The minimum clinically important difference is 0.5. Overall score (average of 15 questions): add up responses to all questions, and divide by 15. |
up to 4 months | |
Secondary | Sino-nasal outcome test (SNOT-22) | This is a 22 item questionnaire. Each item is rated as follows: 0=no problem, 1=very mild problem, 2=mild or slight problem, 3=moderate problem, 4=severe problem, 5=problem as bad as it can be. The score ranges between 0 and 110. A higher score means worse outcome. | up to 4 months | |
Secondary | Change in prescribed maintenance corticosteroid use (inhaled or oral), between baseline and 4 months. | Baseline, 4 months | ||
Secondary | Number of asthma exacerbations requiring at least 3 days of oral corticosteroids | up to 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
||
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|